INTERVACC

Intervacc develop novel veterinary vaccines and the pipeline is based on new technology using recombinant proteins rather than attenuated live strains found in conventional vaccines. This results in vaccines with much lower incidence of side effects usually seen with conventional vaccines, something we take pride in as it greatly contributes to an improved animal welfare... The company have its own sales organisation within the Scandinavian countries through its subsidiary Nordvacc Läkemedel AB. Nordvacc have a long standing history of supplying this market with animal welfare products for over 30 years.

Primary location: